• In June 2026, Quest Diagnostics announced that New York State’s Clinical Laboratory Evaluation Program approved its Haystack MRD liquid biopsy test, allowing nationwide use for detecting residual or recurring solid tumor cancers.
• This approval expands Quest’s oncology toolkit and underscores its push into advanced, data-rich cancer diagnostics that can complement traditional imaging.
• We’ll now examine how nationwide approval of the Haystack MRD test could influence Quest Diagnostics’ investment narrative and growth priorities.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

Quest Diagnostics Investment Narrative Recap

To own Quest Diagnostics, you need to believe its core lab business can steadily compound while newer advanced diagnostics, particularly in oncology, add higher value tests over time. New York’s approval of the Haystack MRD test supports this oncology push, but it does not fundamentally change the near term picture, where productivity gains from automation and managing wage and reimbursement pressures still look like the key swing factors, and high debt remains a central risk.

The Haystack MRD approval sits alongside other recent moves that highlight Quest’s emphasis on advanced testing, such as City of Hope’s multi year trial using Haystack to monitor minimal residual disease in solid tumors. Together, these efforts could reinforce the company’s attempt to deepen its oncology offering, which is one of the areas many investors already view as important for supporting test mix, margins and potential volume resilience if broader reimbursement or policy headwinds materialize.

Yet against this progress, investors should also keep a close eye on Quest’s high debt levels and what they could mean for...

Quest Diagnostics' narrative projects $13.0 billion revenue and $1.4 billion earnings by 2029.

Uncover how Quest Diagnostics' forecasts yield a $223.44 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Two Simply Wall St Community valuations span from US$223.44 to US$315.28, underlining how far apart individual views on Quest’s worth can be. As you weigh those perspectives, it is worth setting them against the company’s push into higher value advanced diagnostics and the possibility that reimbursement changes or payer mix shifts could affect how much of that potential actually shows up in future results.

Explore 2 other fair value estimates on Quest Diagnostics - why the stock might be worth just $223.44!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Quest Diagnostics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Quest Diagnostics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Quest Diagnostics' overall financial health at a glance.

Seeking Other Investments?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Find 44 companies with promising cash flow potential yet trading below their fair value.
• This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.
• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.